Drug intelligence / Profile preview

ERIPTO Protocol

Development stage: Unknown
Lead developer: Affinity Health Research Institute
Modality: Cell Therapies
Administration: Intraarticular

Overview

The ERIPTO Protocol is a combination regenerative therapy developed by the Affinity Health Research Institute for the treatment of post-traumatic osteoarthritis of the knee. It consists of an intra-articular injection of platelet-rich plasma (PRP), hyaluronic acid (HA), and bone marrow aspirate concentrate (BMAC). PRP provides growth factors to stimulate tissue repair, HA acts as a lubricant and shock absorber within the joint, and BMAC provides a source of mesenchymal stem cells and anti-inflammatory cytokines. The protocol aims to delay or prevent the progression of osteoarthritis following joint injury by promoting cartilage health and reducing inflammation.

Other names: PRP + HA + BMAC combinationEarly Regenerative Intervention for Post-Traumatic Osteoarthritis Protocol

Beyond the preview

Go deeper on ERIPTO Protocol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERIPTO Protocol.

Explore the full profile